Eosinophilic esophagitis is a chronic disease that, if not diagnosed and treated, could result in subepithelial fibrosis and esophageal stricture formation. Protheragen stands out as a reputable research service provider engaged in delivering quality preclinical development of drug services specialized in treating eosinophilic esophagitis.

Overview of Eosinophilic Esophagitis

Eosinophilic esophagitis is a form of atopic condition characterized by eosinophilic infiltration of the esophagus which can give rise to multiple upper gastrointestinal symptoms including sore throat, dysphagia, heartburn, and in children abdominal pain and vomiting. There is an increasing prevalence of eosinophilic esophagitis which can be recalled as an antigen-mediated chronic inflammatory disease. This chronic condition is on a steady rise to reach an estimated pooled eosinophilic esophagitis prevalence of 22.7 per 100,000 recently according to a meta-analysis.

Fig.1 Biopsy samples of individual with active eosinophilic esophagitis. (Alkhowaiter S., 2023)

Pathogenesis of Eosinophilic Esophagitis

Eosinophilic esophagitis arises as a result of genetic factors, environmental factors, and immunological factors. In cases where other antigens are presented to a genetically susceptible individual or an individual who has had to overuse antibiotics in childhood or has an atopic background, the esophageal epithelium can secrete alarmins such us IL-33 and thymic stromal lymphopoietin which activate Th2 cells. Those Th2 cells will, in turn, produce IL-13, IL-4, and IL-5 and facilitate eosinophilic migration to the esophagus which leads to a condition where eosinophilic esophagitis people are likely to suffer from esophageal fibrosis.

Fig.2 Key features of eosinophilic esophagitis. (Pilat, J. M., et al., 2024)

Therapeutics Development for Eosinophilic Esophagitis

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Drawing from vast experience in services related to eosinophilic esophagitis, our specialists are in a position to create custom solutions for clients and provide comprehensive preclinical services. Our company with the client at the center to offer diagnostic, therapeutic, and disease model development services.

Therapeutic Development Services

Animal Model Development Services

Widespread use of animal models has been made to elucidate the eosinophilic esophagitis pathogenesis in molecular terms as well as provide a platform for preclinical studies of new therapies. Our company offers a variety of animal model development services that can be tailored to the requirements of the research.

Allergen Induced Model

• Aspergillus fumigatus induced model
• Ovalbumin (OVA) induced model
• Peanut extract-induced model
• Oxazolone induced model
• Recombinant interleukin-induced model

Genetically Engineering Model

• NF-κB–inducing kinase deficient model
• IL-5 transgenic model
• L2-IL5 transgenic model
• CC10-iIL-13 transgenic model
• Others

Using modern methods and technologies, Protheragen offers assistance with pharmacokinetics and safety assessments of drug candidates. We communicate with the clients to formulate their drug development objectives and customize our services accordingly. Clearly defined workflows and efficient management of a project ensure the on-time delivery of high-quality preclinical data. If you are interested in our services, kindly contact us for quotations and further information regarding the services.

References

• Pilat, Jennifer M et al. "Animal models of eosinophilic esophagitis." Journal of leukocyte biology 116.2 (2024): 349-356.
• Alkhowaiter, Saad. "Eosinophilic esophagitis." Saudi medical journal 44.7 (2023): 640-646.
• Uchida, Amiko M et al. "Recent Advances in the Treatment of Eosinophilic Esophagitis." The journal of allergy and clinical immunology. In practice 11.9 (2023): 2654-2663.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.